Fluorofenidone attenuates tubulointerstitial fibrosis by inhibiting TGF-β1-induced fibroblast activation

American Journal of Nephrology

Volumn 34, Issue 2, 2011, Pages 181-194

  Yuan, Qiongjing ^a   Wang, Rui ^a   Peng, Yu ^a   Fu, Xiao ^a   Wang, Wei ^a   Wang, Linghao ^a   Zhang, Fangfang ^a   Peng, Zhangzhe ^a   Ning, Wangbin ^a   Hu, Gaoyun ^b   Wang, Zhaohe ^d   Tao, Lijian ^a,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Faculty of Pharmaceutical Sciences   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d NONE   (China)

Author keywords

AKF PD; Fibroblasts; Mitogen activated protein kinase; Smads pathway; TGF ; Tubulointerstitial fibrosis

Indexed keywords

AKF PD; ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; FLUOROFENIDONE; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PIRFENIDONE; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FIBROBLAST; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUBULOINTERSTITIAL FIBROSIS; UPREGULATION; URETER OBSTRUCTION;

ANIMALS; BODY WEIGHT; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION; KIDNEY; KIDNEY TUBULES; MALE; MAP KINASE KINASE 4; PHOSPHORYLATION; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79960660939     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000329080     Document Type: Article

References (64)

1. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
2. Yhee JY, Yu CH, Kim JH, Sur JH: Effects of T lymphocytes, interleukin-1, and interleukin- 6 on renal fibrosis in canine end-stage renal disease. J Vet Diagn Invest 2008; 20: 585-592.
3. Liu Y: Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217.
4. Eddy AA: Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 353-365.
5. Klahr S: Urinary tract obstruction. Semin Nephrol 2001; 21: 133-145.
6. De Heer E, Sijpkens YW, Verkade M, den Dulk M, Langers A, Schutrups J, Bruijn JA, van Es LA: Morphometry of interstitial fibrosis. Nephrol Dial Transplant 2000; 15(suppl 6):72-73.
7. Yang J, Dai C, Liu Y: Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol 2003; 163: 621-632.
8. Wang W, Liu F, Chen N: Peroxisome proliferator- activated receptor-gamma (PPARgamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. Mediators Inflamm 2007; 2007: 62641.
9. Qi W, Chen X, Poronnik P, Pollock CA: The renal cortical fibroblast in renal tubulointerstitial fibrosis. Int J Biochem Cell Biol 2006; 38: 1-5.
10. Zeisberg M, Strutz F, Muller GA: Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000; 13(suppl 3):S111-S120.
11. Klahr S, Morrissey J: Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002; 283:F861-F875.
12. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC: TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003; 284:F243-F252.
13. Hwang M, Kim HJ, Noh HJ, Chang YC, Chae YM, Kim KH, Jeon JP, Lee TS, Oh HK, Lee YS, Park KK: TGF-beta1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol 2006; 81: 48-54.
14. Sugaru E, Sakai M, Horigome K, Tokunaga T, Kitoh M, Hume WE, Nagata R, Nakagawa T, Taiji M: SMP-534 inhibits TGF-beta-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis. Am J Physiol Renal Physiol 2005; 289:F998-F1004.
15. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A: Targeted disruption of TGF-beta1/ smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486-1494.
16. Ten Dijke P, Goumans MJ, Itoh F, Itoh S: Regulation of cell proliferation by Smad proteins. J Cell Physiol 2002; 191: 1-16.
17. Massague J, Wotton D: Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000; 19: 1745-1754.
18. Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, Gilbert RE, Pollock CA: Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol 2005; 288:F800-F809.
19. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584.
20. Nickl-Jockschat T, Arslan F, Doerfelt A, Bogdahn U, Bosserhoff A, Hau P: An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas. Int J Oncol 2007; 30: 499-507.
21. Bondi CD, Manickam N, Lee DY, Block K, Gorin Y, Abboud HE, Barnes JL: NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol 2010; 21: 93-102.
22. Suzuki H, Uchida K, Nitta K, Nihei H: Role of mitogen-activated protein kinase in the regulation of transforming growth factorbeta- induced fibronectin accumulation in cultured renal interstitial fibroblasts. Clin Exp Nephrol 2004; 8: 188-195.
23. Liu S, Xu SW, Kennedy L, Pala D, Chen Y, Eastwood M, Carter DE, Black CM, Abraham DJ, Leask A: FAK is required for TGFbeta- induced JNK phosphorylation in fibroblasts: Implications for acquisition of a matrix- remodeling phenotype. Mol Biol Cell 2007; 18: 2169-2178.
24. Yu L, Noble NA, Border WA: Therapeutic strategies to halt renal fibrosis. Curr Opin Pharmacol 2002; 2: 177-181.
25. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB: Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2: 906-913.
26. RamachandraRao SP, Zhu Y, Ravasi T, Mc- Gowan TA, Toh I, Dunn SR, Okada S, Shaw MA, Sharma K: Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20: 1765-1775.
27. Cao W, He L, Liu W, Huang Z, Cheng Z: Determination of AKF-PD in whole blood of rat by HPLC-UV. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 833: 257-259.
28. Wang L, Hu GY, Shen H, Peng ZZ, Ning WB, Tao LJ: Fluorofenidone inhibits TGF-beta1 induced CTGF via MAPK pathways in mouse mesangial cells. Pharmazie 2009; 64: 680-684.
29. Tang Y, Li B, Wang N, Xie Y, Wang L, Yuan Q, Zhang F, Qin J, Peng Z, Ning W, Hu G, Li J, Tao L: Fluorofenidone protects mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-1beta release. Int Immunopharmacol 2010; 10: 580-583.
30. Peng ZZ, Hu GY, Shen H, Wang L, Ning WB, Xie YY, Wang NS, Li BX, Tang YT, Tao LJ: Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology (Carlton) 2009; 14: 565-572.
31. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003; 14: 1535-1548.
32. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP: Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199-207.
33. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ: Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 2005; 16: 2702-2713.
34. Broekema M, Harmsen MC, van Luyn MJ, Koerts JA, Petersen AH, van Kooten TG, van Goor H, Navis G, Popa ER: Bone marrowderived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol 2007; 18: 165-175.
35. Lee CI, Guh JY, Chen HC, Hung WC, Yang YL, Chuang LY: Advanced glycation endproduct- induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK- 49F cells. J Cell Biochem 2005; 95: 281-292.
36. Zhang X, Li Y, Dai C, Yang J, Mundel P, Liu Y: Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney. Am J Physiol Renal Physiol 2003; 284:F82-F94.
37. Liu HB, Loo KK, Palaszynski K, Ashouri J, Lubahn DB, Voskuhl RR: Estrogen receptor alpha mediates estrogen's immune protection in autoimmune disease. J Immunol 2003; 171: 6936-6940.
38. Kitamura H, Isaka Y, Takabatake Y, Imamura R, Suzuki C, Takahara S, Imai E: Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant 2008; 23: 1521-1528.
39. Bascands JL, Schanstra JP: Obstructive nephropathy: Insights from genetically engineered animals. Kidney Int 2005; 68: 925-937.
40. Zhong H, Belardinelli L, Maa T, Zeng D: Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32: 2-8.
41. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-350.
42. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY: Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002; 13: 1464-1472.
43. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C: Targeted disruption of Smad3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999; 18: 1280-1291.
44. Huang XR, Chung AC, Wang XJ, Lai KN, Lan HY: Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol 2008; 295:F118-F127.
45. Ma FY, Flanc RS, Tesch GH, Han Y, Atkins RC, Bennett BL, Friedman GC, Fan JH, Nikolic-Paterson DJ: A pathogenic role for cjun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol 2007; 18: 472-484.
46. Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y: Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 2008; 294:F1287-F1295.
47. Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000; 1: 169-178.
48. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, Zhuang S: Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2009; 297:F996-F1005.
49. Das F, Ghosh-Choudhury N, Venkatesan B, Li X, Mahimainathan L, Choudhury GG: Akt kinase targets association of CBP with Smad 3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1. J Cell Physiol 2008; 214: 513-527.
50. Mulder KM: Role of RAS and MAPKS in TGFbeta signaling. Cytokine Growth Factor Rev 2000; 11: 23-35.
51. Fraser D, Brunskill N, Ito T, Phillips A: Longterm exposure of proximal tubular epithelial cells to glucose induces transforming growth factor-beta 1 synthesis via an autocrine PDGF loop. Am J Pathol 2003; 163: 2565-2574.
52. Grotendorst GR: Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997; 8: 171-179.
53. Wahab NA, Weston BS, Mason RM: Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 2005; 307: 305-314.
54. Garrett Q, Khaw PT, Blalock TD, Schultz GS, Grotendorst GR, Daniels JT: Involvement of CTGF in TGF-beta1-stimulation of myofibroblast differentiation and collagen matrix contraction in the presence of mechanical stress. Invest Ophthalmol Vis Sci 2004; 45: 1109-1116.
55. Blom IE, van Dijk AJ, Wieten L, Duran K, Ito Y, Kleij L, deNichilo M, Rabelink TJ, Weening JJ, Aten J, Goldschmeding R: In vitro evidence for differential involvement of CTGF, TGFbeta, and PDGF-BB in mesangial response to injury. Nephrol Dial Transplant 2001; 16: 1139-1148.
56. Yang M, Huang H, Li J, Huang W, Wang H: Connective tissue growth factor increases matrix metalloproteinase-2 and suppresses tissue inhibitor of matrix metalloproteinase- 2 production by cultured renal interstitial fibroblasts. Wound Repair Regen 2007; 15: 817-824
57. Yang M, Huang H, Li J, Li D, Wang H: Tyrosine phosphorylation of the LDL receptorrelated protein (LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation. FASEB J 2004; 18: 1920-1921.
58. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K: Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004; 15: 1430-1440.
59. Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, Sugaya T, Kopp JB, Suzuki H: Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005; 16: 133-143.
60. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A: CTGF expression in mesangial cells: Involvement of Smads, map kinase, and PKC. Kidney Int 2002; 62: 1149-1159.
61. Black SA Jr, Palamakumbura AH, Stan M, Trackman PC: Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: Interactions between cAMP and MAPK signaling pathways, and prostaglandin E2- EP3 receptor mediated activation of the c- JUN N-terminal kinase. J Biol Chem 2007; 282: 15416-15429.
62. Schnaper HW: Renal fibrosis. Methods Mol Med 2005; 117: 45-68.
63. Nishitani Y, Iwano M, Yamaguchi Y, Harada K, Nakatani K, Akai Y, Nishino T, Shiiki H, Kanauchi M, Saito Y, Neilson EG: Fibroblastspecific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. Kidney Int 2005; 68: 1078-1085.
64. Nangaku M: Mechanisms of tubulointerstitial injury in the kidney: Final common pathways to end-stage renal failure. Intern Med 2004; 43: 9-17.